Vyome Holdings, Inc.(HIND)

Biotechnology · Cambridge, MA

$1.95+0.02 (+0.82%)

Delayed quote: Oct 6, 2026, 12:40 PM EDT

Vyome Holdings (HIND) EBITDA Yield: History & Chart | TGMCharts

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:47:43.018Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:47:43.018Z.

Quote observation: 2026-10-06T16:40:27.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -4,205,648
Quote market capitalization: 13,656,656
Total debt · period ending 2026-06-30: 17,310
Cash · period ending 2026-06-30: 7,887,510

FMP input reference: 8dac276dab9b72f767ef95dff0a018bdb1655164ea652fec6d95688d7a2c4747

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

HIND EBITDA Yield Metrics

EBITDA YIELD

N/A

HIND Competitors' EBITDA Yield

HIND

Vyome Holdings, Inc.

Current

Market Cap

$13.66M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs HIND

Market Cap

$13.79M

EBITDA Yield

N/A

TTM Avg

0.87%

3Y Avg

0.87%

5Y Avg

0.87%

SINT

Sintx Technologies, Inc.

vs HIND

Market Cap

$13.83M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs HIND

Market Cap

$13.62M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs HIND

Market Cap

$13.33M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs HIND

Market Cap

$14.13M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PASG

Passage Bio, Inc.

vs HIND

Market Cap

$13.11M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CLRB

Cellectar Biosciences, Inc.

vs HIND

Market Cap

$12.90M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs HIND

Market Cap

$14.57M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTSO

Cytosorbents Corporation

vs HIND

Market Cap

$12.63M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Vyome Holdings, Inc. (HIND)	$13.66M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.79M	N/A	0.87%	0.87%	0.87%
Sintx Technologies, Inc. (SINT)vs ›	$13.83M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.62M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.33M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.13M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$13.11M	N/A	N/A	N/A	N/A
Cellectar Biosciences, Inc. (CLRB)vs ›	$12.90M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.57M	N/A	N/A	N/A	N/A
Cytosorbents Corporation (CTSO)vs ›	$12.63M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

HIND EBITDA Yield Metrics

HIND Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics